Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Reagents, Recombinant Proteins, Ria Kits, RNA
The Relationship of Cholangiocarcinoma with Human Immunodeficiency Virus Cholangiopathy and Cytomegalovirus Infection
The human immunodeficiency virus (HIV) is a disease worldwide with the increasing number of cases globally. Initially, HIV colliaiopati was often observed among these patients but has become rare after three decades due to the availability of new care choices and strong antiretroviral drugs. As a result, the incident now suggests drug resistance or the development of the disease. The relationship between Cholaghiocarcinoma and HIV is still unclear. We report cases of patients with high-grade dysplasia from Choledochus ducts and uncontrolled diseases treated with strong antivirus agents and dilated bile tract.
Learning points: HIV Choligiopathy must be remembered in HIV-positive patients even if they receive combination (train) antiretroviral therapy; Endoscopy Retrograde Choliaiopancreatography can provide symptomatic assistance. After HIV Chorangiopathy is detected, follow-up for Cholangiocarcinoma is needed. Corrected infections can cause choliaiocarcinoma in HIV-positive patients.
The decrease in the incidence of acute rejection without increasing the incidence of cytomegalovirus (CMV) infection in recipients of kidney transplants that accept the anti-thymocyte globulin (RATG) rabbit without prophylactic CMV
Induction therapy with the anti-thymocyte globulin (RATG) rabbit in recipients of low-risk ktridal transplants (KTR) remains controversial, given the increased risk of cytomegalovirus (CMV) infection. This natural experiment compares the clinical results of 12 months in low-risk KTR without CMV prophylaxis (Jan / 3/13-Sep / 16/15) accepting without induction or a single dose of 3mg / kg. We use logistic regression to characterize the pending graft function (DGF), negative binomials to characterize the length of hospitalization of hospitals (LOS) and Cox regression to characterize acute rejection (AR), CMV infection, mistrident of grafting, death and readmission.
The recipient received 3mg / kg Ratg had a risk of 81% lower than AR (AHR 0.14 0.190.25, p <0.001) but there was no increase in hospital admission due to infection (0.911.21, p = 0.5). There is no relationship between 3 mg / kg infection / CMV disease (AHR 0.86 1,101.40, p = 0.5), even when analysis is grouped based on the positive CMV serostatatus (AHR 0.94 1.25 1.65, p = 0, 15) and negative (AHR 0.28 0.57 1.16, p = 0.1). There is no relationship between 3MG / kg Ratg and mortality (AHR 0.51 1,253.08, p = 0.6), loss of grafts (AHR 0.34 0.731.55, p = 0.4). Among the low-risk ktr that does not accept the pharmacological prophylaxis of CMV, induction of 3mg / kg Ratg is associated with a significant reduction in the incidence of AR without an increased risk of CMV infection, regardless of the pre-transplant receiver CMV serostatus.
Lesions such as Degos as a skin manifestation of Cytomegalovirus infection: rare and serious complications in patients with drug induced hypersensitivity syndrome
Cytomegalovirus causes a myriad of clinical features, potentially influencing any organ system, significantly increases morbidity and even mortality. Vascular endothelial cell infections by CyTomeGalovirus have been involved in the development of Vasculopathy, perhaps accounting for clinical relations between Cytomegalovirus and vascular thrombosis. Unlike the involvement of visceral organs, cytomegalovirus skin manifestations varies and are rarely explained. Papulosis of malignant atrophy, which is commonly known as a Degos disease, is an unusual arteriopathic ship with a patognomonic clinical appearance from the middle porcelain-white papules surrounded by erythema Telangiectatic.
Like the arterial occlusive process, Degos may be idiopathic or secondary to autoimmune disorders or viral infections. All in all, presentations such as Degos related to Cytomegalovirus have never been explained. This report illustrates cases where disseminated cytomegalovirus disease is developed 4 weeks after the emergence of hypersensitivity syndrome induced by drugs with skin lesions such as prominent degos. Our case highlights a rare example of lesions such as Degos that occur because of cytomegalovirus disease and emphasizes the importance of early recognition of skin eruption characteristics as a diagnostic instrument that leads to the management of this life-threatening infection.
Cytomegalovirus pancreatitis in immunocompetent patients
Cytomegalovirus (CMV) is a DNA virus whose double strand, which infects most of the adult population. In immunocompetent patients, usually asymptomatic or manifest as symptoms of mild flu and self-limit, while in immunocompromised patients, CMV can cause significant disease. Here we report cases of unusual CMV pancreatitis in the 75-year-old woman’s immunocompetent. Patients develop severe significant pancreatic necrosis that failed non-operative management, and ultimately underwent the Pancreatic Necrosectomy. Then, he developed three spontaneous gastric perforations.

The first two perforations were managed operatively, but after the third perforation family decided not to undergo other operations. The diagnosis of CMV pancreatitis is based on pancreatic histopathology and confirms with a rapid response to Ganciclovir. The patient immediately began at Ganciclovir Intravenous (IV) which resulted in clinical recovery and he remained without symptoms of more than one year post op. This is a rare case of CMV pancreatitis with gastric perforation in immunocompetent patients. The level of suspicion is high and the right maintenance is important for such a clinical scenario.
Microvascular and structural abnormalities extralesional in cytomegalovirus retinitis
To evaluate extraesional microvascular and structural changes from the macula using Optical Coherence Tomography Angiography (Octa) and Structural October in the Citomegalovirus Retinitis (CMVR). A CMVR patient observational study was conducted. Complete ophthalmic examination, serial color fundus fundus, structural October and Octa are carried out at the beginning and follow-up visits up to 12 months. The structural OCT was analyzed to evaluate the macular area inside, bordering and exceed CMVR lesions.
Plexus extraledional retina capillaries from maculas are evaluated with October angiography and compared to fellow eyes that are not affected. Thirteen eyes from 13 registered patients. On the basis, the macular area without CMVR lesions showed a decrease in ship density (VD) of both superficial (p = 0,0002) and inside (p <0.0001) the retinal capillary plexus in the eye with CMVR compared to the area of the macular not affected by fellow eyes that are not affected. The decrease in VD survives through the follow-up period of up to 12 months after adjusting the degree of vitreous fog.
anti- TTC39B antibody |
FNab09086 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against TTC39B |
TTC39B Antibody, HRP conjugated |
1-CSB-PA713348LB01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
TTC39B Antibody, FITC conjugated |
1-CSB-PA713348LC01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
TTC39B Antibody, Biotin conjugated |
1-CSB-PA713348LD01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
Human TTC39B shRNA Plasmid |
20-abx965852 |
Abbexa |
|
|
|
Mouse TTC39B shRNA Plasmid |
20-abx977074 |
Abbexa |
|
|
|
Rat TTC39B shRNA Plasmid |
20-abx988909 |
Abbexa |
|
|
|
TTC39B Recombinant Protein (Human) |
RP033328 |
ABM |
100 ug |
Ask for price |
TTC39B Recombinant Protein (Rat) |
RP235163 |
ABM |
100 ug |
Ask for price |
TTC39B Recombinant Protein (Mouse) |
RP182057 |
ABM |
100 ug |
Ask for price |
Polyclonal TTC39B Antibody (C-term) |
APR03519G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TTC39B (C-term). This antibody is tested and proven to work in the following applications: |
Ttc39b ORF Vector (Rat) (pORF) |
ORF078389 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Ttc39b ORF Vector (Mouse) (pORF) |
ORF060687 |
ABM |
1.0 ug DNA |
EUR 607.2 |
TTC39B ORF Vector (Human) (pORF) |
ORF011110 |
ABM |
1.0 ug DNA |
EUR 114 |
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx145789-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx026040-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx026040-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx239086-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
Ttc39b sgRNA CRISPR Lentivector set (Rat) |
K6591501 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Ttc39b sgRNA CRISPR Lentivector set (Mouse) |
K4952201 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
TTC39B sgRNA CRISPR Lentivector set (Human) |
K2551101 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
HNRRabbit pAb Rabbit pAb |
A17497-100ul |
Abclonal |
100 ul |
EUR 369.6 |
HNRRabbit pAb Rabbit pAb |
A17497-200ul |
Abclonal |
200 ul |
EUR 550.8 |
HNRRabbit pAb Rabbit pAb |
A17497-20ul |
Abclonal |
20 ul |
EUR 219.6 |
HNRRabbit pAb Rabbit pAb |
A17497-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPC1 Rabbit pAb |
A14872-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPC1 Rabbit pAb |
A14872-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPC1 Rabbit pAb |
A14872-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPC1 Rabbit pAb |
A14872-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPC5 Rabbit pAb |
A9997-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPC5 Rabbit pAb |
A9997-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPC5 Rabbit pAb |
A9997-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPC5 Rabbit pAb |
A9997-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPC4 Rabbit pAb |
A5948-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPC4 Rabbit pAb |
A5948-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPC4 Rabbit pAb |
A5948-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPC4 Rabbit pAb |
A5948-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPN1 Rabbit pAb |
A6041-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPN1 Rabbit pAb |
A6041-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPN1 Rabbit pAb |
A6041-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPN1 Rabbit pAb |
A6041-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPC3 Rabbit pAb |
A18370-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPC3 Rabbit pAb |
A18370-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPC3 Rabbit pAb |
A18370-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPC3 Rabbit pAb |
A18370-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 1) |
K6591502 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 2) |
K6591503 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 3) |
K6591504 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K4952202 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K4952203 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K4952204 |
ABM |
1.0 ug DNA |
EUR 184.8 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 1) |
K2551102 |
ABM |
1.0 ug DNA |
EUR 184.8 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 2) |
K2551103 |
ABM |
1.0 ug DNA |
EUR 184.8 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 3) |
K2551104 |
ABM |
1.0 ug DNA |
EUR 184.8 |
TTC39B Protein Vector (Human) (pPB-C-His) |
PV044437 |
ABM |
500 ng |
EUR 394.8 |
TTC39B Protein Vector (Human) (pPB-N-His) |
PV044438 |
ABM |
500 ng |
EUR 394.8 |
TTC39B Protein Vector (Human) (pPM-C-HA) |
PV044439 |
ABM |
500 ng |
EUR 394.8 |
TTC39B Protein Vector (Human) (pPM-C-His) |
PV044440 |
ABM |
500 ng |
EUR 394.8 |
TTC39B 3'UTR GFP Stable Cell Line |
TU077428 |
ABM |
1.0 ml |
EUR 1672.8 |
Ttc39b 3'UTR GFP Stable Cell Line |
TU272613 |
ABM |
1.0 ml |
Ask for price |
Ttc39b 3'UTR GFP Stable Cell Line |
TU171312 |
ABM |
1.0 ml |
Ask for price |
Ttc39b 3'UTR Luciferase Stable Cell Line |
TU222613 |
ABM |
1.0 ml |
Ask for price |
TTC39B Protein Vector (Rat) (pPB-C-His) |
PV313554 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Rat) (pPB-N-His) |
PV313555 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Rat) (pPM-C-HA) |
PV313556 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Rat) (pPM-C-His) |
PV313557 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Mouse) (pPB-C-His) |
PV242746 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Mouse) (pPB-N-His) |
PV242747 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Mouse) (pPM-C-HA) |
PV242748 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Mouse) (pPM-C-His) |
PV242749 |
ABM |
500 ng |
EUR 723.6 |
Ttc39b 3'UTR Luciferase Stable Cell Line |
TU121312 |
ABM |
1.0 ml |
Ask for price |
TTC39B 3'UTR Luciferase Stable Cell Line |
TU027428 |
ABM |
1.0 ml |
EUR 1672.8 |
Elk (Ser383) ? Rabbit* Polyclonal Antibody |
ABP-PAB-21010 |
Allele Biotech |
100 ug |
Ask for price |
|
PPIA Rabbit pAb |
A0113-100ul |
Abclonal |
100 ul |
EUR 369.6 |
PPIA Rabbit pAb |
A0113-200ul |
Abclonal |
200 ul |
EUR 550.8 |
PPIA Rabbit pAb |
A0113-20ul |
Abclonal |
20 ul |
Ask for price |
PPIA Rabbit pAb |
A0113-50ul |
Abclonal |
50 ul |
Ask for price |
EMD Rabbit pAb |
A0116-100ul |
Abclonal |
100 ul |
EUR 369.6 |
EMD Rabbit pAb |
A0116-200ul |
Abclonal |
200 ul |
EUR 550.8 |
EMD Rabbit pAb |
A0116-20ul |
Abclonal |
20 ul |
Ask for price |
EMD Rabbit pAb |
A0116-50ul |
Abclonal |
50 ul |
Ask for price |
PDIA3 Rabbit pAb |
A0117-100ul |
Abclonal |
100 ul |
EUR 369.6 |
PDIA3 Rabbit pAb |
A0117-200ul |
Abclonal |
200 ul |
EUR 550.8 |
PDIA3 Rabbit pAb |
A0117-20ul |
Abclonal |
20 ul |
Ask for price |
PDIA3 Rabbit pAb |
A0117-50ul |
Abclonal |
50 ul |
Ask for price |
INPP5D Rabbit pAb |
A0122-100ul |
Abclonal |
100 ul |
EUR 369.6 |
INPP5D Rabbit pAb |
A0122-200ul |
Abclonal |
200 ul |
EUR 550.8 |
INPP5D Rabbit pAb |
A0122-20ul |
Abclonal |
20 ul |
EUR 219.6 |
INPP5D Rabbit pAb |
A0122-50ul |
Abclonal |
50 ul |
EUR 267.6 |
KRT17 Rabbit pAb |
A0123-100ul |
Abclonal |
100 ul |
EUR 369.6 |
KRT17 Rabbit pAb |
A0123-200ul |
Abclonal |
200 ul |
EUR 550.8 |
KRT17 Rabbit pAb |
A0123-20ul |
Abclonal |
20 ul |
EUR 219.6 |
KRT17 Rabbit pAb |
A0123-50ul |
Abclonal |
50 ul |
EUR 267.6 |
PBX1 Rabbit pAb |
A0124-100ul |
Abclonal |
100 ul |
EUR 369.6 |
PBX1 Rabbit pAb |
A0124-200ul |
Abclonal |
200 ul |
EUR 550.8 |
PBX1 Rabbit pAb |
A0124-20ul |
Abclonal |
20 ul |
EUR 219.6 |
PBX1 Rabbit pAb |
A0124-50ul |
Abclonal |
50 ul |
EUR 267.6 |
NCSTN Rabbit pAb |
A0128-100ul |
Abclonal |
100 ul |
EUR 369.6 |
NCSTN Rabbit pAb |
A0128-200ul |
Abclonal |
200 ul |
EUR 550.8 |
NCSTN Rabbit pAb |
A0128-20ul |
Abclonal |
20 ul |
EUR 219.6 |
NCSTN Rabbit pAb |
A0128-50ul |
Abclonal |
50 ul |
EUR 267.6 |
FEN1 Rabbit pAb |
A0129-100ul |
Abclonal |
100 ul |
EUR 369.6 |
FEN1 Rabbit pAb |
A0129-200ul |
Abclonal |
200 ul |
EUR 550.8 |
FEN1 Rabbit pAb |
A0129-20ul |
Abclonal |
20 ul |
Ask for price |
FEN1 Rabbit pAb |
A0129-50ul |
Abclonal |
50 ul |
Ask for price |
LRP5 Rabbit pAb |
A0130-100ul |
Abclonal |
100 ul |
EUR 369.6 |
LRP5 Rabbit pAb |
A0130-200ul |
Abclonal |
200 ul |
EUR 550.8 |
LRP5 Rabbit pAb |
A0130-20ul |
Abclonal |
20 ul |
EUR 219.6 |
LRP5 Rabbit pAb |
A0130-50ul |
Abclonal |
50 ul |
EUR 267.6 |
CBX5 Rabbit pAb |
A0132-100ul |
Abclonal |
100 ul |
EUR 369.6 |
CBX5 Rabbit pAb |
A0132-200ul |
Abclonal |
200 ul |
EUR 550.8 |
CBX5 Rabbit pAb |
A0132-20ul |
Abclonal |
20 ul |
Ask for price |
CBX5 Rabbit pAb |
A0132-50ul |
Abclonal |
50 ul |
Ask for price |
BCL2A1 Rabbit pAb |
A0134-100ul |
Abclonal |
100 ul |
EUR 369.6 |
BCL2A1 Rabbit pAb |
A0134-200ul |
Abclonal |
200 ul |
EUR 550.8 |
BCL2A1 Rabbit pAb |
A0134-20ul |
Abclonal |
20 ul |
Ask for price |
BCL2A1 Rabbit pAb |
A0134-50ul |
Abclonal |
50 ul |
Ask for price |
TERF1 Rabbit pAb |
A0137-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TERF1 Rabbit pAb |
A0137-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TERF1 Rabbit pAb |
A0137-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TERF1 Rabbit pAb |
A0137-50ul |
Abclonal |
50 ul |
EUR 267.6 |
TERF2 Rabbit pAb |
A0138-100ul |
Abclonal |
100 ul |
EUR 460.8 |
TERF2 Rabbit pAb |
A0138-200ul |
Abclonal |
200 ul |
Ask for price |
TERF2 Rabbit pAb |
A0138-20ul |
Abclonal |
20 ul |
Ask for price |
TERF2 Rabbit pAb |
A0138-50ul |
Abclonal |
50 ul |
EUR 318 |
SPHK1 Rabbit pAb |
A0139-100ul |
Abclonal |
100 ul |
EUR 369.6 |
SPHK1 Rabbit pAb |
A0139-200ul |
Abclonal |
200 ul |
EUR 550.8 |
SPHK1 Rabbit pAb |
A0139-20ul |
Abclonal |
20 ul |
EUR 219.6 |
SPHK1 Rabbit pAb |
A0139-50ul |
Abclonal |
50 ul |
EUR 267.6 |
NCK1 Rabbit pAb |
A0140-100ul |
Abclonal |
100 ul |
EUR 369.6 |
NCK1 Rabbit pAb |
A0140-200ul |
Abclonal |
200 ul |
EUR 550.8 |
NCK1 Rabbit pAb |
A0140-20ul |
Abclonal |
20 ul |
Ask for price |
NCK1 Rabbit pAb |
A0140-50ul |
Abclonal |
50 ul |
Ask for price |
MAP2K2 Rabbit pAb |
A0143-100ul |
Abclonal |
100 ul |
EUR 369.6 |
MAP2K2 Rabbit pAb |
A0143-200ul |
Abclonal |
200 ul |
EUR 550.8 |
MAP2K2 Rabbit pAb |
A0143-20ul |
Abclonal |
20 ul |
Ask for price |
MAP2K2 Rabbit pAb |
A0143-50ul |
Abclonal |
50 ul |
Ask for price |
MAP2K6 Rabbit pAb |
A0145-100ul |
Abclonal |
100 ul |
EUR 369.6 |
MAP2K6 Rabbit pAb |
A0145-200ul |
Abclonal |
200 ul |
EUR 550.8 |
MAP2K6 Rabbit pAb |
A0145-20ul |
Abclonal |
20 ul |
Ask for price |
MAP2K6 Rabbit pAb |
A0145-50ul |
Abclonal |
50 ul |
Ask for price |
SLC9A3R1 Rabbit pAb |
A0146-100ul |
Abclonal |
100 ul |
EUR 369.6 |
SLC9A3R1 Rabbit pAb |
A0146-200ul |
Abclonal |
200 ul |
EUR 550.8 |
SLC9A3R1 Rabbit pAb |
A0146-20ul |
Abclonal |
20 ul |
EUR 219.6 |
SLC9A3R1 Rabbit pAb |
A0146-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Bmi1 Rabbit pAb |
A0147-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Bmi1 Rabbit pAb |
A0147-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Bmi1 Rabbit pAb |
A0147-20ul |
Abclonal |
20 ul |
Ask for price |
Bmi1 Rabbit pAb |
A0147-50ul |
Abclonal |
50 ul |
Ask for price |
UCHL1 Rabbit pAb |
A0148-100ul |
Abclonal |
100 ul |
EUR 369.6 |
UCHL1 Rabbit pAb |
A0148-200ul |
Abclonal |
200 ul |
EUR 550.8 |
UCHL1 Rabbit pAb |
A0148-20ul |
Abclonal |
20 ul |
EUR 219.6 |
UCHL1 Rabbit pAb |
A0148-50ul |
Abclonal |
50 ul |
EUR 267.6 |
DCX Rabbit pAb |
A0149-100ul |
Abclonal |
100 ul |
EUR 369.6 |
DCX Rabbit pAb |
A0149-200ul |
Abclonal |
200 ul |
EUR 550.8 |
DCX Rabbit pAb |
A0149-20ul |
Abclonal |
20 ul |
Ask for price |
DCX Rabbit pAb |
A0149-50ul |
Abclonal |
50 ul |
Ask for price |
TRAF1 Rabbit pAb |
A0150-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TRAF1 Rabbit pAb |
A0150-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TRAF1 Rabbit pAb |
A0150-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TRAF1 Rabbit pAb |
A0150-50ul |
Abclonal |
50 ul |
EUR 267.6 |
GNB2L1 Rabbit pAb |
A0151-100ul |
Abclonal |
100 ul |
EUR 369.6 |
GNB2L1 Rabbit pAb |
A0151-200ul |
Abclonal |
200 ul |
EUR 550.8 |
GNB2L1 Rabbit pAb |
A0151-20ul |
Abclonal |
20 ul |
EUR 219.6 |
GNB2L1 Rabbit pAb |
A0151-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Macular structural characteristics on the limits and outside the lesions include intrarinal hyperreflective points, macular sistoid edema, subretinal fluid and loss of ellipsoid zone (EZ). Selective EZ losses found in 6 of 12 eyes showed recovery in 4 eyes after receiving anti-virus treatment. In the eye of CMVR, there are microvascular abnormalities and microstructure in the macular area without cmvr lesions that are clinically seen. Our results provide interesting insights into Retina CMV infection.